PYC Therapeutics Limited Stock
Stocks
PYC
AU000000PYC7
Biotechnology & Medical Research
OTC Markets Traded|
Market Closed -
Australian S.E.
02:12:16 2026-10-02 EDT
|
5-day change | 1st Jan Change | ||
| 2.460 AUD | -1.99% |
|
-12.77% | +48.64% |
| 09-10 | PYC Therapeutics Says First Patient Dosed in Open-Label Extension of Drug Candidate Study in Polycystic Kidney Disease | MT |
| 09-03 | PYC Therapeutics Limited - Special Call |
| Market Cap | 2.42B 1.68B 1.49B 1.39B 1.27B 2.4B 162B 16.88B 6.54B 82.64B 6.31B 6.18B 265B | P/E 2027 * |
-31.9x | P/E 2028 * | -28.6x |
|---|---|---|---|---|---|
| Enterprise Value | 1.94B 1.35B 1.2B 1.12B 1.02B 1.92B 130B 13.53B 5.24B 66.24B 5.06B 4.95B 213B | EV / Sales 2027 * |
-
| EV / Sales 2028 * | - |
| Free-Float |
66.17% | Yield 2027 * |
-
| Yield 2028 * | - |
| Markets | Quality | ||
|---|---|---|---|
Australian S.E.
| PYC | Delayed | |
OTC Markets
| PYCXF | Delayed |
Last Transcript: PYC Therapeutics Limited
| 03-16 | Bell Potter rates PYC as Speculative Buy | AQ |
| 25-09-08 | Bell Potter rates PYC as Speculative Buy | AQ |
| 24-11-07 | PYC Therapeutics : Anti Bribery & Anti Corruption Policy | PU |
| 24-11-07 | PYC Therapeutics : Definition of Independence | PU |
| 24-11-07 | PYC Therapeutics : Continuous Disclosure Policy | PU |
| 1 day | -1.99% | ||
| 1 week | -12.77% | ||
| Current month | -8.21% | ||
| 1 month | -4.28% | ||
| 3 months | +60.26% | ||
| 6 months | +120.63% | ||
| Current year | +48.64% |
| 1 week | 2.44 |  | 2.84 |
| 1 month | 2.19 | | 2.93 |
| Current year | 1.04 | | 2.93 |
| 1 year | 1.04 | | 2.93 |
| 3 years | 0.52 | | 2.93 |
| 5 years | 0.5 | | 2.93 |
| 10 years | 0.15 | | 2.93 |
| Manager | Title | Age | Since |
|---|---|---|---|
Rohan Hockings
CEO | Chief Executive Officer | 42 | 2020-08-18 |
Thomas Ulmer
DFI | Director of Finance/CFO | 47 | 2026-07-06 |
Candice Junge
CTO | Chief Tech/Sci/R&D Officer | - | 2025-07-31 |
| Director | Title | Age | Since |
|---|---|---|---|
Rohan Hockings
BRD | Director/Board Member | 42 | 2018-11-29 |
Ian Constable
BRD | Director/Board Member | - | 2025-09-21 |
Peter Coleman
CHM | Chairman | 66 | 2025-11-17 |
| Date | Insider | Type | Main position | Quantity | % Market Cap. | Importance |
|---|---|---|---|---|---|---|
| 8/13/26 | Free | Chief Executive Officer | 4,598,662 | 0.4676% | ||
| 8/13/26 | Free | Chief Executive Officer | 10,477,965 | 1.0654% | ||
| 8/13/26 | Free | Chief Executive Officer | 7,706,503 | 0.7836% |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -1.99% | -12.77% | +115.79% | +303.28% | 1.68B | |
| +4.16% | +3.04% | +49.37% | +94.17% | 74.16B | |
| -3.11% | -3.53% | +20.19% | +81.44% | 57.39B | |
| +0.89% | -0.63% | +2.17% | +36.19% | 47.64B | |
| +0.36% | +0.81% | +342.39% | +742.40% | 44.29B | |
| -0.96% | -4.50% | +24.96% | +35.38% | 42.5B | |
| -0.20% | -0.77% | +4.13% | +105.50% | 40.71B | |
| -0.54% | +2.93% | +9.31% | +50.41% | 30.97B | |
| -2.68% | +2.92% | +29.33% | +22.72% | 28.53B | |
| +0.05% | -1.64% | -8.14% | -11.37% | 24.34B | |
| Average | -0.40% | -1.81% | +58.95% | +146.01% | 39.22B | |
| Weighted average by Cap. | +0.11% | -0.89% | +57.21% | +138.97% |
| 2027 * | 2028 * | |
|---|---|---|
| Net sales | - | - |
| Net income | -78.66M -54.67M -48.57M -45.34M -41.32M -77.93M -5.26B -549M -213M -2.69B -205M -201M -8.62B | -86.4M -60.05M -53.35M -49.8M -45.39M -85.6M -5.77B -603M -234M -2.95B -225M -221M -9.47B |
| Net Debt | -480M -334M -296M -277M -252M -476M -32.08B -3.35B -1.3B -16.4B -1.25B -1.23B -52.63B | -456M -317M -281M -263M -239M -451M -30.44B -3.18B -1.23B -15.56B -1.19B -1.16B -49.94B |
| Date | Price | Change | Volume |
|---|---|---|---|
| 26-10-02 | A$2.460 | -1.99% | 1,219,518 |
| 26-10-01 | A$2.510 | -6.34% | 1,677,046 |
| 26-09-30 | A$2.680 | -3.25% | 3,741,769 |
| 26-09-29 | A$2.770 | +0.73% | 3,147,785 |
| 26-09-28 | A$2.750 | -2.48% | 2,130,618 |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Quarterly revenue - Rate of surprise
- Stock Market
- Stocks
- PYC Stock
Select your edition
All financial news and data tailored to specific country editions
